Description
Research Overview
RETA + ELORA is a multi-component investigational research blend combining RETA and ELORA. The labelled 12.5 MG composition consists of 10 MG RETA and 2.5 MG ELORA
RETA Research
RETA is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. Clinical research has investigated its pharmacology and metabolic effects in obesity and type 2 diabetes.
ELORA Research
ELORA is an investigational long-acting amylin receptor agonist being studied in metabolic research. Early clinical research has evaluated its pharmacokinetics, tolerability and effects on bodyweight-related measures.
Scientific Context
The two compounds act through distinct receptor systems and are being investigated separately in clinical development. Research involving either compound individually should not be interpreted as evidence establishing the safety or efficacy of the combined RETA + ELORA formulation.
Important Research Note
RETA + ELORA remains an investigational research blend. The combination itself should be considered distinct from the clinical evidence generated for either component individually. This product is supplied for research purposes only and is not intended to represent a treatment for obesity, diabetes or any other human condition.
For research purposes only. Not intended for human or veterinary use.
